Absci is trading at $10.27, up 5.39%, after announcing preliminary details of its Phase 2 STORYLINE trial of AI-designed ABS-201 for endometriosis.
- The planned global study will evaluate efficacy and safety in approximately 150 participants across 10 or more countries.
- Initiation is anticipated in mid-2027, subject to regulatory clearance.
- The company-specific clinical-development milestone appears to be the primary catalyst despite broader biotech weakness.